Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Nature1mon
What is the role of ursodeoxycholic acid in therapy for PSC?
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123 , 1238–1251 (2002). Article CAS PubMed Google Scholar ...
Daily11d
Ursodeoxycholic acid may Reduce need of Cholecystectomy for gallstones after laparoscopic sleeve gastrectomy: Study
Reduce the need for Cholecystectomy for gallstones after laparoscopic sleeve gastrectomy suggests a study published in the BMC Surgery.In this study, we aimed ...
WebMD29d
Livdelzi: A New Treatment Option for Primary Biliary Cholangitis
Livdelzi is usually taken together with another medicine for PBC called ursodeoxycholic acid (also called ursodiol or urso). Livdelzi was studied in 193 people with PBC. The people in the ...
The Pharma Letter5d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Here's why Shilpa Medicare share price jumped 8% in trade on February 13
The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...